Presentation is loading. Please wait.

Presentation is loading. Please wait.

Surya Chitra, PhD MBA Director Biostatistics Endo Health Solutions

Published byDavid Cross Modified over 6 years ago

Similar presentations

Presentation on theme: "Surya Chitra, PhD MBA Director Biostatistics Endo Health Solutions"— Presentation transcript:

1 Surya Chitra, PhD MBA Director Biostatistics Endo Health Solutions
Noninferiority Trials in Drug Development: Clinical, Statistical and Regulatory Perspective Surya Chitra, PhD MBA Director Biostatistics Endo Health Solutions                                    ……………………………………………………………..……………  AMS    Endo Pharmaceuticals    HealthTronics    Qualitest

2 Industry Innovation & Growth
Increasing trend in conducting Noninferiority trials in drug development will continue as more drugs are approved. Although this trend will make interpretation of trial results more challenging, it can provide opportunities for new outcomes for patients.

3 Learning Objectives Identity the crucial role of noninferiority trials in drug development. How to manage risk with noninferiority /superiority trials. Evaluate strategies for implementing noninferiority trials. Identify the challenges and opportunities with noninferiority trials Session Level = Intermediate

4 Agenda Wednesday, June 26, 2013 (4:00 PM – 5:30 PM)
Start Time (Approx) Topic Speaker 4:05 PM Challenges Related to Noninferiority Tests: An Overview Yusong Chen, PhD 4:30 PM Noninferiority Margin Determination Using Dirichlet Process and Power Priors Ram Tiwari, PhD 4:55 PM Practical Experiences with Design and Analysis of Noninferiority Clinical Trials in Infectious Diseases  Ulysses Diva, PhD 5:20 PM Q & A All

5

Download ppt "Surya Chitra, PhD MBA Director Biostatistics Endo Health Solutions"

Similar presentations

Labeling claims for patient- reported outcomes (A regulatory perspective) FDA/Industry Workshop Washington, DC September 16, 2005 Lisa A. Kammerman, Ph.D.

Labeling claims for patient- reported outcomes (A regulatory perspective) FDA/Industry Workshop Washington, DC September 16, 2005 Lisa A. Kammerman, Ph.D.
The Statisticians Role in Pharmaceutical Development

The Statisticians Role in Pharmaceutical Development
OEMBA Information Systems Course James R. Coakley PhD, Accounting Information Systems Minor in Statistics and Computer Science MBA BS, Math/Computer Science.

OEMBA Information Systems Course James R. Coakley PhD, Accounting Information Systems Minor in Statistics and Computer Science MBA BS, Math/Computer Science.
Copyright (c) Li Zhu 20031 Biostatistics and Its Role in Public Health Li Zhu, PhD Assistant Professor of Biostatistics Department of Epidemiology and.

Copyright (c) Li Zhu Biostatistics and Its Role in Public Health Li Zhu, PhD Assistant Professor of Biostatistics Department of Epidemiology and.
The ICH E5 Question and Answer Document Status and Content Robert T. O’Neill, Ph.D. Director, Office of Biostatistics, CDER, FDA Presented at the 4th Kitasato-Harvard.

The ICH E5 Question and Answer Document Status and Content Robert T. O’Neill, Ph.D. Director, Office of Biostatistics, CDER, FDA Presented at the 4th Kitasato-Harvard.
Jean Maguire van Seventer School of Public Health Eldon Strickland Office of Distance Education 1 An Online Strategy to Translate Basic Concepts into Real.

Jean Maguire van Seventer School of Public Health Eldon Strickland Office of Distance Education 1 An Online Strategy to Translate Basic Concepts into Real.
Moisés Navarro Director, Strategy & Services, Global Cloud Services Telefónica, S.A. Cloud computing: what does it mean for Europe? 1 st. Digital Agenda.

Moisés Navarro Director, Strategy & Services, Global Cloud Services Telefónica, S.A. Cloud computing: what does it mean for Europe? 1 st. Digital Agenda.
ONDQA Perspective on Post Approval Changes Eric P. Duffy, PhD Director, Division of Post-Market Evaluation, ONDQA, CDER, FDA Public Meeting: Supplements.

ONDQA Perspective on Post Approval Changes Eric P. Duffy, PhD Director, Division of Post-Market Evaluation, ONDQA, CDER, FDA Public Meeting: Supplements.
3rd Baltic Conference on Medicines Economic Evaluation, Reimbursement and Rational Use of Pharmaceuticals Pricing and Reimbursement of Pharmaceuticals.

3rd Baltic Conference on Medicines Economic Evaluation, Reimbursement and Rational Use of Pharmaceuticals Pricing and Reimbursement of Pharmaceuticals.
National Summit on Preventing Pharmaceutical Waste October 19, 2010 University of the Sciences Philadelphia, Pennsylvania 1 October 19, 2010Prepared by.

National Summit on Preventing Pharmaceutical Waste October 19, 2010 University of the Sciences Philadelphia, Pennsylvania 1 October 19, 2010Prepared by.
INTRODUCTION TO RA.

INTRODUCTION TO RA.
Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical Science, CDER, FDA ACPS Subcommittee on Manufacturing Science: Identification and Prioritization.

Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical Science, CDER, FDA ACPS Subcommittee on Manufacturing Science: Identification and Prioritization.
Clinical Trial Review and Approval: New Regulations and their implications Siddika Mithani, Ph.D Clinical Trials & Special Access Programme Therapeutic.

Clinical Trial Review and Approval: New Regulations and their implications Siddika Mithani, Ph.D Clinical Trials & Special Access Programme Therapeutic.
ISPOR POLAND CHAPTER Polish Society of Pharmacoeconomics (PTFe )

ISPOR POLAND CHAPTER Polish Society of Pharmacoeconomics (PTFe )
The Practical Art of Endpoint Selection: Industry Perspectives A View from the Pharma Industry of the FDA Guidance on PROs Glenn A. Phillips, Ph.D. Director.

The Practical Art of Endpoint Selection: Industry Perspectives A View from the Pharma Industry of the FDA Guidance on PROs Glenn A. Phillips, Ph.D. Director.
Quality Improvement at the Crossroads AcademyHealth Annual Research Meeting Washington, DC - June 9, 2008.

Quality Improvement at the Crossroads AcademyHealth Annual Research Meeting Washington, DC - June 9, 2008.
Health challenges in an enlarged Europe Report from Parallel Session A1 Dr. Natasha Azzopardi Muscat Ministry of Health - Malta.

Health challenges in an enlarged Europe Report from Parallel Session A1 Dr. Natasha Azzopardi Muscat Ministry of Health - Malta.
Proposal for End-of-Phase 2A (EOP2A) Meetings Advisory Committee for Pharmaceutical Sciences Clinical Pharmacology Subcommittee November 17-18, 2003 Lawrence.

Proposal for End-of-Phase 2A (EOP2A) Meetings Advisory Committee for Pharmaceutical Sciences Clinical Pharmacology Subcommittee November 17-18, 2003 Lawrence.
Current Challenges and Future Developments in HTA in the UK Frances Macdonald, 23 rd September 2008 (A personal, Industry View)

Current Challenges and Future Developments in HTA in the UK Frances Macdonald, 23 rd September 2008 (A personal, Industry View)
Health Roundtable – 2008 – Improving Clinical Management Presenter: (delegate name) Hospital: (your hospital code name) Key contact person for this project.

Health Roundtable – 2008 – Improving Clinical Management Presenter: (delegate name) Hospital: (your hospital code name) Key contact person for this project.

Similar presentations

Ads by Google